# When a Hazard Ratio Is Too Good

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good

> Three observational studies this month reported mortality reductions of 78%, 91% and 47%. Nothing in medicine does that. One rule explains all three, and it also shows which rows in the same papers to keep.

## Key points

- All-cause mortality HR 0.219 in psoriasis, a 78% reduction that is not a drug effect.
- Same pattern three times this month: 0.09, 0.219, 0.53. Different populations, one mechanism.
- The skill is separating rows INSIDE one paper: its cardiac figure of 0.561 is believable.
- Ask what a real effect that size would mean. Usually the answer settles it.

A study of people with psoriasis found those taking a GLP-1 had **78% lower all-cause mortality** than those on other diabetes and obesity drugs.[1] Nothing in medicine reliably cuts all-cause mortality by three quarters, not even statins, blood pressure treatment or smoking cessation. When a number looks like that, it is usually telling you about the patients rather than the drug.

That figure is the third of its kind we have read this month, and a fourth has since turned up in [a study of seizure recurrence](https://glpwatchdog.org/research/seizures-when-you-already-have-epilepsy). The confounding this argument rests on has also now been measured rather than inferred: people with a mental health diagnosis have roughly a quarter the odds of being prescribed one of these drugs and half again the odds of being put on insulin (see [a quarter as likely to be offered it](https://glpwatchdog.org/research/a-quarter-as-likely-to-be-offered-it)). For the constructive counterpart (an observational study reporting effects just as large that *does* deserve trust, and the specific techniques that earn it), see [how to trust an observational study](https://glpwatchdog.org/research/how-to-trust-an-observational-study).

## The pattern, three times over

*All-cause mortality hazard ratios reported in observational GLP-1 studies covered on this site this month.*

| Population | Hazard ratio | Comparator |
| --- | --- | --- |
| Breast cancer with diabetes | 0.09 | Insulin or metformin — and *no difference* against SGLT2 inhibitors in the same paper |
| Psoriasis | 0.219 | Other antidiabetic and antiobesity drugs |
| [Kidney transplant recipients](https://glpwatchdog.org/research/glp1-after-a-kidney-transplant) | 0.53 | Non-users, pooled across four studies |

Each appeared in a real journal, with matching, adjustment and sensitivity analyses. None is fraudulent. If a drug did produce any of those effects, it would be the most important medicine of the century, which is a useful sanity check on its own.

> Ask what a true effect of this size would mean. If the answer is “the greatest advance in the history of medicine”, look at the comparison group.

## What produces numbers like this

One mechanism explains all three: the people who receive a newer, more expensive, more demanding drug are not like the people who do not.

1. **They are well enough to be prescribed it.** Clinicians do not start a weight-loss drug in someone acutely unwell, frail, or approaching end of life. Those patients stay in the comparison group and die at the rate very sick people die.
2. **They are engaged with care.** Getting and staying on one of these drugs requires appointments, prescriptions, prior authorizations and money. That selects for people already doing better on every axis.
3. **The comparator is often a marker of severity.** Insulin marks advanced diabetes. “Other antiobesity drugs” can mark people who failed or could not tolerate the newer option.

None of that is measurable in a claims database, so no amount of statistical adjustment removes it. Matching equalizes what was recorded, and the strongest predictors of death (frailty, functional status, whether someone is quietly dying) are largely not recorded.

## The tell inside this particular study

The psoriasis paper reports something its authors treat as a finding and which reads more naturally as a warning: the risk reductions were *markedly higher* in people with psoriasis than in cohorts with obesity or diabetes but without it.[1]

A biological story could be told about that: psoriasis is inflammatory, and these drugs reduce inflammatory markers. But there is a duller explanation. In a population with more comorbidity, prescribing is more selective, so the gap between who gets the newer drug and who does not grows wider. A differential that tracks how sick the population is, rather than tracking anything about the disease mechanism, is the signature of confounding rather than of biology.

## Which rows to believe in the same study

This is the part that matters, because the answer is not “ignore the paper”. The same study reports figures that are entirely plausible.

- **Major adverse cardiac events, HR 0.561.** Consistent in size and direction with [randomized cardiovascular outcome trials](https://glpwatchdog.org/research/lists/top-glp1-cardiovascular-studies). Believable.
- **Alcohol abuse 0.346 and substance abuse 0.510.** Larger, but consistent with a randomized trial in alcohol use disorder and with national cohort data on substance use. Worth taking seriously.
- **No increase in typical adverse drug events.** A null in a large sample, which is the kind of finding observational data handles well.
- **All-cause mortality 0.219.** Not believable as a drug effect, for the reasons above.

> **All-cause mortality is the outcome most vulnerable to this problem**, precisely because everything affects it. A specific endpoint, such as a heart attack, a documented flare or a lab value, is harder for unmeasured frailty to drive. When a study’s specific outcomes look reasonable and its all-cause mortality looks miraculous, the mortality figure is the one to discard.

## The rule, portable

1. **Find the comparison group before the result.** Lower than what?
2. **Distrust hazard ratios below about 0.5 in non-randomized data.** They usually describe who was prescribed the drug. One semaglutide-versus-tirzepatide study reached 0.43 only after [dropping the people who stopped](https://glpwatchdog.org/research/two-studies-one-comparison-two-answers).
3. **Check whether the effect survives a fair comparator.** In the breast cancer study it vanished entirely against a modern one.
4. **Weight specific outcomes above all-cause mortality** in observational work.
5. **Ask what a real effect that size would mean.** Usually the answer settles it.

Applied across this month’s reading, that rule keeps the cardiovascular, infection and psychiatric findings and discards three mortality figures. It separates evidence about the drugs from arithmetic about who gets prescribed them.

## Frequently asked questions

### Do GLP-1 drugs cut mortality by 78%?

No. A psoriasis cohort reported an all-cause mortality hazard ratio of 0.219, but nothing in medicine reliably reduces all-cause mortality by three quarters. Figures like that describe who receives the drug: people well enough to be prescribed it and engaged enough to stay on it.

### Why can't statistical adjustment fix this?

Because matching only equalizes what was recorded, and the strongest predictors of death (frailty, functional status, whether someone is quietly dying) are largely absent from claims data. You cannot adjust for a variable nobody wrote down.

### Does that mean the whole study is worthless?

No, and that is the useful skill. The same study's cardiac outcome of 0.561 is consistent with randomized trials, and its alcohol and substance-use findings match other work. The all-cause mortality figure is the one to discard, not the paper.

### Why is all-cause mortality especially vulnerable?

Because everything affects it. A specific endpoint, such as a heart attack, a lab value or a documented flare, is harder for unmeasured frailty to drive. When specific outcomes look reasonable and mortality looks miraculous, mortality is the suspect number.

### What is the quickest test?

Ask what a real effect of that size would mean. If the answer is that it would be the most important medicine of the century, go and look at the comparison group.

## References

1. Olbrich H, Kridin K, Zirpel H, et al. Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study. British Journal of Dermatology. 2025. PMID: 40897378. https://pubmed.ncbi.nlm.nih.gov/40897378/

---

Cite as: GLP Watchdog, Nora Bissett, "When a Hazard Ratio Is Too Good", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good

Canonical HTML page: https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
